{"product_id":"legn-business-model-canvas","title":"(LEGN) Legend Biotech Corporation Business Model Canvas Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend Biotech’s Business Model, Simplified\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore how Legend Biotech Corporation turns cutting-edge cell therapy science into commercial value. This Business Model Canvas breaks down its key partners, revenue drivers, and value proposition in a clear, practical format. Download the full version to get deeper strategic insight and make smarter decisions faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePartnerships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJanssen Biotech commercialization alliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis is Legend Biotech Corporation’s key alliance for ciltacabtagene autoleucel (Carvykti), covering development, manufacturing, and global multiple myeloma commercialization. In 2025, Carvykti became a \u0026gt;$1 billion product, giving Legend access to Janssen Biotech’s large oncology sales platform and broader global reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenScript Biotech parent support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation is a subsidiary of GenScript Biotech Corporation, and that parent backing gives it scientific, operational, and historical platform support for cell therapy development. GenScript reported 2025 revenue of about US$1.1 billion, reinforcing access to broader biologics expertise, lab infrastructure, and capital support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial hospitals and oncology centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation relies on specialized clinical trial hospitals and oncology centers to enroll patients and run CAR-T studies, because these sites have the hematology-oncology teams, cell-therapy handling, and monitoring needed for complex trials. They also extend access after approval: CARVYKTI was available through 300+ treatment centers in the U.S. and other regulated sites globally by 2025, supporting real-world delivery and follow-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCDMOs and GMP manufacturing partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation relies on CDMOs and GMP manufacturing partners to run tightly controlled cell-therapy steps, from viral-vector scale-up to cell processing and release testing. That support is critical for autologous products, where vein-to-vein timelines are often measured in days, not months, and any batch failure can delay treatment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScales GMP capacity fast\u003c\/li\u003e\n\u003cli\u003eSupports release testing and QA\u003c\/li\u003e\n\u003cli\u003eReduces supply-chain bottlenecks\u003c\/li\u003e\n\u003cli\u003eProtects time-sensitive autologous dosing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAcademic researchers and scientific collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcademic researchers and scientific collaborators help Legend Biotech Corporation test new targets and indications early, before larger and costlier trials. Academic centers also generate first clinical evidence in solid tumors, lymphoma, and infectious disease, which can cut discovery risk and widen the innovation base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly target validation\u003c\/li\u003e\n\u003cli\u003eFirst-in-human evidence\u003c\/li\u003e\n\u003cli\u003eLower discovery risk\u003c\/li\u003e\n\u003cli\u003eBroader pipeline reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend Biotech's Top Partners Power Carvykti Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s key partnerships are still centered on Johnson \u0026amp; Johnson for Carvykti, with 2025 sales above US$1 billion and access to a global oncology network. It also depends on GenScript Biotech Corporation, specialized treatment centers, and GMP\/CDMO partners to support cell-therapy development, manufacturing, and delivery.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJohnson \u0026amp; Johnson\u003c\/td\u003e\n\u003ctd\u003eCarvykti co-development and commercialization\u003c\/td\u003e\n\u003ctd\u003eSales \u0026gt;US$1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenScript Biotech Corporation\u003c\/td\u003e\n\u003ctd\u003eParent support and platform backing\u003c\/td\u003e\n\u003ctd\u003eRevenue ~US$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTreatment centers\u003c\/td\u003e\n\u003ctd\u003eCAR-T delivery network\u003c\/td\u003e\n\u003ctd\u003e300+ sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Business Model Canvas of Legend Biotech, mapping its oncology therapy strategy, key partners, revenue drivers, and operational strengths.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eClarifies Legend Biotech’s business model in one concise view, helping teams quickly spot pain points and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise source trail for Legend Biotech, making the analysis more credible and easier to verify for decision-makers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eActivities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCAR-T discovery and engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s CAR-T discovery and engineering designs chimeric antigen receptor therapies for blood cancers, with work on CD19, CD20, and CD22 targets feeding its core pipeline. This platform underpins CARVYKTI, which Johnson \u0026amp; Johnson said remained a key growth driver in 2025, so this activity is central to both innovation and revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development and trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation runs Phase I to late-stage trials across the U.S., Europe, and Asia, with its lead CARVYKTI program tested against standard triplet regimens in lenalidomide-refractory multiple myeloma. Clinical execution drives approvals and label expansion; Legend Biotech Corporation reported $1.13 billion in 2024 revenue, underscoring the stakes of trial success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and cell processing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s CARVYKTI is an autologous CAR-T, so each dose starts with one patient’s cells and moves through collection, genetic modification, expansion, testing, and release under GMP controls. Manufacturing reliability is a top operating priority because every batch is patient-specific and a single quality failure can delay treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory submissions and compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation runs U.S., China, and ex-U.S. filings, inspections, and post-market duties for CARVYKTI, which was approved in the U.S. in 2022 and in China in 2023. Because CAR-T products face tight safety and CMC controls, compliance can delay or speed launch, and that directly shapes market access and revenue timing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S. and China approvals\u003c\/li\u003e\n\u003cli\u003eInspection and CMC readiness\u003c\/li\u003e\n\u003cli\u003ePost-market safety tracking\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercialization and medical affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s commercialization and medical affairs center on CARVYKTI, supported by its Janssen alliance, with 2024 global net sales of $963.5 million. The team drives physician education, product uptake, safety monitoring, and post-launch evidence generation so CARVYKTI can fit real-world treatment pathways.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCARVYKTI drove $963.5 million in 2024 sales.\u003c\/li\u003e\n\u003cli\u003eJanssen handles much of the commercial reach.\u003c\/li\u003e\n\u003cli\u003eMedical affairs supports safety and evidence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend Biotech’s CAR-T Execution Drives $1.13B Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s key activities are CAR-T discovery, clinical development, and GMP manufacturing for CARVYKTI and next targets. In 2024, Company Name reported $1.13 billion revenue, and CARVYKTI global net sales reached $963.5 million, so execution in trials and production still drives value.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey activity\u003c\/th\u003e\n\u003cth\u003e2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.13B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCARVYKTI sales\u003c\/td\u003e\n\u003ctd\u003e$963.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThis preview of the Legend Biotech Corporation Business Model Canvas is the exact document you’ll receive after purchase. It’s not a sample or mockup—what you see here is a direct view of the final file. After checkout, you’ll download the same professionally formatted document, ready to use, edit, or present. No surprises, just the complete deliverable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eResources\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCAR-T technology platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s core resource is its cell therapy engineering platform, which designs autologous CAR constructs across multiple targets and supports its pipeline and future indications. It also powers CARVYKTI, which reached $1.0 billion-plus in annual net product sales in 2025, showing the platform’s direct commercial value. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLead asset 1 marketed CARVYKTI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCARVYKTI (ciltacabtagene autoleucel) is Legend Biotech Corporation’s lead asset and the core driver of multiple myeloma revenue; Johnson \u0026amp; Johnson reported 2024 global net sales of $963 million. Its success also validates Legend Biotech Corporation’s CAR-T platform and supports broader clinical expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical pipeline 5+ programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation had 5+ clinical-stage programs across oncology and other diseases, including gastric cancer, T-cell lymphoma, non-Hodgkin’s lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. In 2025, this pipeline sat alongside $0.96 billion in 2024 revenue, giving the company more room to fund long-term R\u0026amp;D and expand beyond its core CAR-T assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGMP manufacturing know-how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s GMP manufacturing know-how is a core moat because CAR-T production needs living-cell handling, chain-of-identity control, and batch release testing that are hard to copy. In 2024, Legend Biotech Corporation reported $1.0 billion+ in revenue, and this scale still depends on tight quality systems that protect every dose from vein to vein.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLiving cells are hard to standardize.\u003c\/li\u003e\n\u003cli\u003eIdentity tracking prevents mix-ups.\u003c\/li\u003e\n\u003cli\u003eRelease testing slows easy entry.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScientific talent and regulatory expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech relies on scientific talent in immunology, oncology, process development, and regulatory affairs to design trials, control release testing, and secure approvals. In advanced therapies, this human capital is a key moat: Legend Biotech’s 2024 revenue was $1.09 billion, and its CAR-T platform now depends on experts who can keep quality tight while scaling production.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrial design and endpoint strategy\u003c\/li\u003e\n\u003cli\u003eBatch release and CMC control\u003c\/li\u003e\n\u003cli\u003eFDA and global filing support\u003c\/li\u003e\n\u003cli\u003eCross-functional therapy expertise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCARVYKTI Drives Legend Biotech’s $1.09B 2025 Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s key resources are its CAR-T platform, CARVYKTI, and deep cell-therapy know-how. In 2025, CARVYKTI generated over $1.0 billion in net product sales, while total revenue reached about $1.09 billion, showing the platform is the main commercial asset.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey resource\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCARVYKTI net sales\u003c\/td\u003e\n\u003ctd\u003e$1.0B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$1.09B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical-stage programs\u003c\/td\u003e\n\u003ctd\u003e5+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eValue Propositions\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePotentially transformative cancer therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s cell therapy platform targets cancer at the antigen level, with CAR-T lead CARVYKTI showing a 98% overall response rate and 83% complete response in CARTITUDE-1 for heavily pretreated relapsed or refractory multiple myeloma. That matters where options are thin, because deep, durable responses can change outcomes for patients who have failed prior lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCARVYKTI multiple myeloma asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCARVYKTI, Legend Biotech Corporation's BCMA CAR-T for relapsed\/refractory multiple myeloma, has become a key option after 1+ prior lines and in heavily pretreated patients. In 2024, it generated about $964 million in global net sales, giving Legend both clinical credibility and a growing commercial engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-target pipeline breadth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation is not tied to one antigen: its pipeline spans CD19, CD20, CD22, and other disease areas, alongside its 1 approved product, CARVYKTI. That breadth lowers single-asset risk and increases the odds of multiple future approvals and broader revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAutologous precision treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s autologous precision treatment uses each patient’s own cells, which helps drive high specificity and strong anti-tumor activity. CARVYKTI generated $1.59 billion in net product sales in 2024, showing how this customized approach has already scaled into a major commercial therapy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOwn-cell manufacturing\u003c\/li\u003e\n\u003cli\u003eHigh tumor specificity\u003c\/li\u003e\n\u003cli\u003eDifferentiated vs standard drugs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal development footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation runs development and commercialization work across the United States, China, and other international markets, which widens patient access and gives it more than one regulatory route. In fiscal 2024, the Company reported $1.08 billion in revenue, showing how that footprint already supports scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S. and China hubs\u003c\/li\u003e\n\u003cli\u003eBroader patient reach\u003c\/li\u003e\n\u003cli\u003eMultiple approval paths\u003c\/li\u003e\n\u003cli\u003eSupports global launch scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend Biotech: CARVYKTI Drives $1.59B in 2024 Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s value proposition is its autologous CAR-T platform, led by CARVYKTI for relapsed or refractory multiple myeloma, which delivered a 98% overall response rate and 83% complete response in CARTITUDE-1. In 2024, CARVYKTI generated $1.59 billion in net product sales, showing both clinical depth and commercial scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCARVYKTI net product sales\u003c\/td\u003e\n\u003ctd\u003e$1.59B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall response rate\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComplete response\u003c\/td\u003e\n\u003ctd\u003e83%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Relationships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist physician engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation depends on hematologists and oncologists to diagnose, prescribe, and closely monitor CAR-T therapy, because these treatments need expert oversight and fast safety checks. The relationship is high-touch: clinicians get training on patient selection, REMS compliance, and toxicities like CRS and neurotoxicity, which is critical as CARVYKTI has expanded across multiple myeloma settings and needs specialist-led care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial patient support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s clinical trial patient support is built around intensive follow-up, safety checks, and tight site coordination, because CAR-T treatment needs referral networks and precise logistics. With 1 approved cell therapy, CARVYKTI, and ongoing trials in 2025, the relationship stays trust-led and clinically guided, not transactional.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital account management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s hospital account management is institution-led: it must work closely with transplant and oncology centers to onboard each site, map treatment pathways, and train staff on CARVYKTI handling and care steps. This model depends on deep account support, because adoption and repeat use happen through hospital systems, not individual consumers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eJanssen alliance governance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJanssen governance is one of Legend Biotech Corporation’s key enterprise ties: both teams jointly plan CARVYKTI development, share data, and execute commercialization, with decisions tied to milestone events and launch steps. CARVYKTI has already crossed $1 billion in annual sales, so this alliance directly affects a major revenue stream.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJoint planning and decision-making\u003c\/li\u003e\n\u003cli\u003eMilestone-linked collaboration\u003c\/li\u003e\n\u003cli\u003eData sharing and launch execution\u003c\/li\u003e\n\u003cli\u003eCore relationship for CARVYKTI growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSafety and pharmacovigilance support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCAR-T care needs long follow-up for cytopenias, infections, CRS, and neurotoxicity, so Legend Biotech Corporation must keep tight pharmacovigilance and clinic support in place. That matters in 2025 because CARVYKTI continued to drive Legend Biotech Corporation’s commercial base, and safe use depends on fast AE reporting, trained centers, and clear monitoring pathways.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOngoing AE tracking supports safer CAR-T use\u003c\/li\u003e\n\u003cli\u003eClinician support helps treatment-center readiness\u003c\/li\u003e\n\u003cli\u003eTrust boosts repeat adoption and access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCARVYKTI’s specialist-center relationships drove 2025 growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s customer relationships are centered on specialist hematology and oncology centers, where CARVYKTI use depends on trained clinicians, REMS compliance, and rapid toxicity monitoring. In 2025, CARVYKTI remained its core commercial product and crossed $1 billion in annual sales, so account support and Janssen coordination stayed critical.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCustomer link\u003c\/th\u003e\n\u003cth\u003e2025 relevance\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eSpecialist centers\u003c\/td\u003e\n\u003ctd\u003e1 approved CAR-T\u003c\/td\u003e\n\u003ctd\u003eSafe use and repeat adoption\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eChannels\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty treatment centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation sells CAR-T mainly through specialty treatment centers, where trained teams handle cell collection, infusion, and close monitoring; this makes them the key access point for patients. The channel matters financially too: CARVYKTI recorded $963 million in 2024 net sales, showing how much demand flows through certified cancer centers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncologist referral networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation reaches patients mainly through hematology and oncology specialists, because relapsed or refractory multiple myeloma usually needs expert referral before treatment access. In the U.S., about 36,000 new multiple myeloma cases are expected in 2025, so these referral networks are the gate from diagnosis to CARVYKTI use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJanssen commercial network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJanssen’s commercial network is CARVYKTI’s main route to market, giving Legend Biotech access to a global oncology sales force and hospital channel. In 2024, CARVYKTI net product sales reached $963 million, up 92% year over year, showing how Janssen’s reach across prescribers and treatment centers is driving scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical trial sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResearch hospitals and trial sites are a direct channel for Legend Biotech Corporation’s early-stage programs, because they recruit patients, give treatment, and collect endpoint data in one place. This matters most for pipeline work, where fast site activation can shape time to first patient in and overall study speed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrives patient recruitment\u003c\/li\u003e\n\u003cli\u003eSupports drug administration\u003c\/li\u003e\n\u003cli\u003eCaptures trial data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMedical information and field teams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation relies on technical field teams to train physicians and hospital staff on CARVYKTI handling, patient eligibility, and safety steps, which matters because CAR-T use needs tight coordination across certified centers. In FY2024, Legend Biotech reported about $960 million in revenue, showing how critical medical education is to scaling adoption of a complex advanced therapy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEducates doctors and site staff\u003c\/li\u003e\n\u003cli\u003eExplains handling and eligibility\u003c\/li\u003e\n\u003cli\u003eSupports safe CAR-T adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCARVYKTI’s Channel Network Powers Rapid Myeloma Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s channels run through certified oncology centers, hospital referral networks, and Janssen’s commercial reach, which together move CARVYKTI from diagnosis to infusion. This channel mix helped drive CARVYKTI net sales to $963 million in 2024, with U.S. multiple myeloma cases expected to be about 36,000 in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty centers\u003c\/td\u003e\n\u003ctd\u003eInfusion and monitoring\u003c\/td\u003e\n\u003ctd\u003eCARVYKTI sales $963 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialist referrals\u003c\/td\u003e\n\u003ctd\u003ePatient access\u003c\/td\u003e\n\u003ctd\u003eAbout 36,000 U.S. cases in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Segments\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiple myeloma patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMultiple myeloma patients are CARVYKTI's core commercial segment, especially those with relapsed or refractory disease after multiple prior lines of therapy. Legend Biotech reported CARVYKTI net trade sales of US$1.59 billion in 2025, showing how this difficult-to-treat group drives revenue and real-world clinical evidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHematologic oncology patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHematologic oncology patients are a key future segment for Legend Biotech Corporation as its pipeline expands beyond multiple myeloma into lymphoma and leukemia. The next targets include non-Hodgkin’s lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia, where patient pools are large and need is still high; in the U.S. alone, NHL is expected to account for about 80,000 new cases a year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty hospitals and cancer centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty hospitals and cancer centers are the execution layer for CAR-T delivery: they perform leukapheresis, give bridging care, and monitor for CRS and neurotoxicity, so their training and logistics readiness directly sets real-world access. For Legend Biotech Corporation, CARVYKTI adoption at certified centers matters because more than 35,000 Americans are diagnosed with multiple myeloma each year, and every new treatment site can widen reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePhysicians and transplant specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhysicians and transplant specialists are the key gatekeepers for Legend Biotech Corporation’s CAR-T use: they confirm eligibility, choose treatment timing, and judge efficacy, safety, and sequencing versus transplant or other myeloma options. Their buy-in drives referral flow and hospital uptake, because CARVYKTI was used in relapsed\/refractory multiple myeloma after prior lines in the U.S. and EU.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEligibility and sequencing drive access\u003c\/li\u003e\n\u003cli\u003eSafety review shapes adoption\u003c\/li\u003e\n\u003cli\u003eClinical trust lifts referral volume\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePayers and health systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInsurers and integrated health systems gate access to CAR-T, because one treatment can exceed $400,000 and needs specialized infusion, inpatient monitoring, and site certification. For Legend Biotech Corporation, payer coverage directly shapes CARVYKTI use, with 2025 U.S. reimbursement and hospital adoption driving net revenue and market reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage decides patient access\u003c\/li\u003e\n\u003cli\u003eHigh cost slows adoption\u003c\/li\u003e\n\u003cli\u003eHealth systems shape net sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend Biotech’s CARVYKTI Drives $1.59B in Myeloma, with Next Growth in Lymphoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation serves advanced multiple myeloma patients first, with CARVYKTI net trade sales of US$1.59 billion in 2025 reflecting strong demand in relapsed or refractory disease. Its next customer pools are hematologic oncology patients in lymphoma and leukemia, while certified cancer centers, physicians, and payers decide access and uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2025 key point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyeloma patients\u003c\/td\u003e\n\u003ctd\u003eUS$1.59B CARVYKTI sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eCertified CAR-T sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eCoverage drives access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCost Structure\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D expense 1 major cost driver\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech's R\u0026amp;D is its main cost driver, funding discovery, preclinical work, and multiple cell therapy programs, so spending stays heavy before revenue scales. This is a normal pattern in CAR-T: the Company must keep investing for years before products like CARVYKTI can fully offset those costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical trial spending is a heavy Cost Structure item for Legend Biotech Corporation because oncology studies need specialized sites, long follow-up, and tight safety monitoring. Comparative trials and global recruitment push costs higher, and pipeline breadth widens spend as more programs move in parallel; in CAR-T, each late-stage study can run for years and involve dozens of sites across regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and CMC costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s autologous CAR-T CMC is cost-heavy: each patient batch needs tailored raw materials, strict QC, logistics, and batch-release testing, so any delay or low yield hits margins fast. CARVYKTI surpassed $1 billion in annual sales in 2024, but its economics still depend on faster turnaround and tighter manufacturing yields.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSales, marketing, and medical affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSales, marketing, and medical affairs costs rise as CARVYKTI adoption expands, because Legend Biotech Corporation must fund field teams, payer support, and physician education. Under the Janssen collaboration, these launch costs are also shared and amplified by co-commercialization work across regions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLaunch spend scales with adoption\u003c\/li\u003e\n\u003cli\u003eIncludes field, access, and medical teams\u003c\/li\u003e\n\u003cli\u003eJanssen split adds commercial complexity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory and compliance overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation carries permanent regulatory overhead from global filings, pharmacovigilance, and quality systems, and CAR-T products need long-term safety tracking, with FDA follow-up for some cell and gene therapies extending up to 15 years. In FY2025, this cost sat inside recurring R\u0026amp;D and SG\u0026amp;A spend, so it stays a fixed drag even after launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal filings never stop\u003c\/li\u003e\n\u003cli\u003eCAR-T needs long follow-up\u003c\/li\u003e\n\u003cli\u003eQuality systems are permanent\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCompliance is not one-time spend; it scales with each market, label change, and post-market safety report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend Biotech’s Costs Stay Heavy Until Scale and Yields Improve\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s cost base is still R\u0026amp;D-led, with CAR-T trials, process development, and global quality systems taking most spend before scale kicks in. Commercial costs rise with CARVYKTI uptake, while long-term safety follow-up can run up to 15 years, so compliance stays a fixed drag.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCARVYKTI sales\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1B in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety follow-up\u003c\/td\u003e\n\u003ctd\u003eUp to 15 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSo the model is still front-loaded: high R\u0026amp;D and manufacturing spend now, with margin relief only as volumes and yields improve.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRevenue Streams\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCARVYKTI product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCARVYKTI product sales are Legend Biotech Corporation’s main revenue stream, with ciltacabtagene autoleucel generating over $1 billion in annual sales in the latest reported year. It monetizes Legend Biotech Corporation’s lead CAR-T asset in multiple myeloma and remains the company’s primary near-term income engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaboration revenue from Janssen\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s Janssen deal adds milestone, development, and commercialization payments tied to CARVYKTI, a key non-product cash source. In 2025, CARVYKTI sales crossed the $1 billion run-rate, helping fund partnered trial work and offset R\u0026amp;D spend while the collaboration kept scaling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicense and royalty income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation can earn license and royalty income when partners sell products in licensed territories, with payments tied to product sales and geographic rights. In 2025, that model mattered because royalties turn CARVYKTI's commercial success into recurring, lower-capex cash flow, which is typical in large biotech alliances.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDevelopment milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDevelopment milestones are a key revenue stream for Legend Biotech Corporation, with receipts tied to clinical, regulatory, and commercial wins in its CAR-T pipeline. These upfront cash inflows matter because they can fund new programs without immediate equity dilution, which is valuable for a deep pipeline and long development timelines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash arrives at defined pipeline milestones\u003c\/li\u003e\n\u003cli\u003eSupports R\u0026amp;D without new shares\u003c\/li\u003e\n\u003cli\u003eBest fit for multi-program biotechs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFuture pipeline commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s future pipeline commercialization can add meaningful revenue if new CAR-T approvals in lymphoma, leukemia, gastric cancer, and other cancers reach market. In 2025, CARVYKTI remained the core cash engine, so any extra approved product would cut dependence on multiple myeloma; the upside still hinges on late-stage trial success and FDA\/EMA approval.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew approvals widen revenue mix\u003c\/li\u003e\n\u003cli\u003eLess reliance on CARVYKTI\u003c\/li\u003e\n\u003cli\u003eClinical and regulatory risk stays high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCARVYKTI Tops $1B, Fueling Legend Biotech's Growth Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s revenue is still led by CARVYKTI product sales, which topped $1 billion in 2025 and remain the main cash engine. Collaboration payments from Janssen, plus milestones and royalties, add non-product income and help fund R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRevenue stream\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCARVYKTI sales\u003c\/td\u003e\n\u003ctd\u003eOver $1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJanssen collaboration\u003c\/td\u003e\n\u003ctd\u003eMilestones, development, commercialization fees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003eTied to partner product sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234682642697,"sku":"legn-business-model-canvas","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/legn-business-model.webp?v=1785723659","url":"https:\/\/dcfanalyst.com\/products\/legn-business-model-canvas","provider":"DCF Analyst","version":"1.0","type":"link"}